Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Participants

Next Previous
Search
Trial Profile

A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK-8527 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MK-8527-004
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 06 Mar 2024 Results assessing ascending single doses (trial A) and ascending multiple doses (trial B) of MK-8527 in adults (aged 18-55 years) without HIV assessing safety and pharmacokinetics, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
    • 06 Mar 2024 Results (n=31) of pooled data from NCT03615183 and NCT05494736 assessing the antiretroviral activity of MK-8527 in treatment-naive participants with HIV-1 for the 1-mg dose group presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 28 Feb 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top